Our team has a wealth of experience and expertise in the development of protein/peptide therapeutics and an in-depth understanding of the needs of the pharmaceutical industry when it comes to the development and manufacture of novel, effective and safe biologics. In addition, with our business acumen and experience of forming strategic alliances we are working to build effective partnerships to deliver biologics solutions:
Dr Lisa Patel | Non-Exec Director
Lisa is Chief Scientific Officer of IP Group's Biotech division and its drug development subsidiary, Modern Biosciences. Prior to joining IP Group, she spent 10 years at GlaxoSmithKline, where she worked across the drug discovery process as a team-leader, taking projects from target identification to candidate selection. Latterly, she was a group leader in Clinical Pharmacology and Discovery Medicine, supporting the translation of projects through Phase 2 proof-of-concept studies. As CSO at Modern Biosciences, Lisa has taken the company's lead rheumatoid arthritis programme from early discovery molecules into clinical studies using a virtual, outsourced drug discovery model, while also winning £4 million of government grants and helping to raise over £8 million in financing. Lisa holds a degree in Biochemistry from Imperial College, London, a PhD in molecular genetics and an MBA.